A Phase 3, Randomized, Open-Label Trial Comparing Efficacy and Safety of RAY1225 Versus Semaglutide as Add-on Therapy to Oral Antidiabetic Drugs in Patients With Type 2 Diabetes
RAY1225, a GLP-1 receptor agonist from Guangdong Raynovent Biotech, is being tested head-to-head against semaglutide as add-on therapy to oral antidiabetic drugs in adults with type 2 diabetes. The open-label phase 3 trial targets 600 participants with expected completion in December 2026, measuring HbA1c reduction as the primary endpoint. This represents another Chinese biotech company attempting to challenge Novo Nordisk's semaglutide dominance in the established GLP-1 diabetes market. The direct comparator design suggests confidence in differentiation, though the open-label format may limit regulatory acceptance versus blinded superiority trials.